News
ATRA
0.7147
-0.54%
-0.0039
Weekly Report: what happened at ATRA last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at ATRA last week (0408-0412)?
Weekly Report · 04/15 09:09
Weekly Report: what happened at ATRA last week (0401-0405)?
Weekly Report · 04/08 09:10
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Grants 3,750 restricted stock units of Atara’s common stock to one newly hired employee. Atara is a leader in T-cell immunotherapy. The company is leveraging its novel allogeneic Epstein-Barr virus (EBV) T- cell platform to develop transformative therapies for patients with cancer and autoimmune diseases.
Barchart · 04/05 15:01
Atara Biotherape: Statement of changes in beneficial ownership of securities
Press release · 04/03 01:05
Atara Biotherapeutics Price Target Cut to $2.30/Share From $4.80 by Stifel
Dow Jones · 04/01 15:06
Atara Biotherapeutics Is Maintained at Hold by Stifel
Dow Jones · 04/01 15:06
Stifel Maintains Hold on Atara Biotherapeutics, Lowers Price Target to $2.3
Benzinga · 04/01 14:55
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
TipRanks · 04/01 11:30
ATARA BIOTHERAPEUTICS INC <ATRA.O>: STIFEL CUTS TARGET PRICE TO $2.3 FROM $4.8
Reuters · 04/01 10:59
Weekly Report: what happened at ATRA last week (0325-0329)?
Weekly Report · 04/01 09:10
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Affimed (AFMD) and Atara Biotherapeutics (ATRA) have neutral ratings from analysts. The analysts are neither bullish nor bearish on the stocks. Affimed has an analyst consensus of Moderate Buy with a $15.00 average price target.
TipRanks · 04/01 02:20
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
Eric Dobmeier, a board member of Atara Biotherapeutics, Inc., has decided not to seek re-election at the 2024 Annual Meeting. His departure is not due to any conflict with the company’s management or board. ATRA stock is down 1.7%.
TipRanks · 03/29 20:43
Atara Biotherapeutics Full Year 2023 Earnings: Revenues Disappoint
Atara Biotherapeutics missed analyst estimates by 53%. The company's shares are up 3.7% from a week ago. Revenue is forecast to grow 33% p.a. On average during the next 3 years. The company has 6 warning signs for investors to be aware of before investing in Atara.
Simply Wall St · 03/29 11:11
Atara Biotherapeutics’ Profitability Hinges on Partners’ Success with Ebvallo Amid Market Challenges
TipRanks · 03/29 06:00
Atara Biotherapeutics (ATRA) Gets a Buy from TD Cowen
TipRanks · 03/28 20:06
Atara Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Atara Biotherapeutics Inc reports results for the quarter ended in December. Revenue rose 1,824% to $4.25 million from a year ago. The company reported a quarterly adjusted loss of 56 cents per share. The mean expectation of six analysts was for a loss of 48 cents.
Reuters · 03/28 13:40
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/28 13:40
Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M
Atara Biotherapeutics Q4 GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M. Atara expects to report Q4 results on March 28, 2024.
Seeking Alpha · 03/28 12:43
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.